Targeting postprandial hyperglycaemia in patients with type 2 diabetes: Nateglinide vs acarbose

被引：0
|
作者：
Holmes, D
Raccah, D
Escobar-Jimenez, F
Standl, E
机构：
[1] Novartis Pharma, Basel, Switzerland
[2] Novartis Pharma, Marseille, France
[3] Novartis Pharma, Granada, Spain
[4] Novartis Pharma, Munich, Germany
来源：
DIABETOLOGIA | 2001年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
825
引用
下载
收藏
页码：A215 / A215
页数：1
相关论文
共 50 条
  • [1] Targeting postprandial hyperglycemia to achieve glycemic control in patients with type 2 diabetes: A comparison of nateglinide and acarbose
    Standl, E
    Raccah, D
    Quesada, M
    Holmes, D
    DIABETES, 2001, 50 : A445 - A445
  • [2] Effects of Nateglinide Versus Acarbose on Postprandial Plasma Glucose Excursion and Postprandial Lipid Profiles in Patients with Type 2 Diabetes
    Lu, Juming
    Lv, Xiaofeng
    Xue, Yaoming
    Guo, Xiaohui
    Li, Yanbing
    Yan, Li
    DIABETES, 2011, 60 : A291 - A292
  • [3] Both Nateglinide and Acarbose Improve Postprandial Ghrelin Response in Patients With Newly Diagnosed Type 2 Diabetes
    Zheng, Fenping
    Yin, Xueyao
    Lu, Weina
    Zhou, Jiaqiang
    Li, Hong
    DIABETES, 2012, 61 : A703 - A704
  • [4] Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia
    Damato, A. Bellomo
    Stefanelli, G.
    Laviola, L.
    Giorgino, R.
    Giorgino, F.
    DIABETIC MEDICINE, 2011, 28 (05) : 560 - 566
  • [5] Predictors of postprandial hyperglycaemia in patients with type 2 diabetes
    Nita, C. A.
    Rusu, A.
    Bala, C. G.
    Hancu, N.
    DIABETOLOGIA, 2008, 51 : S430 - S430
  • [6] Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes
    Kim, Mi K.
    Suk, Ji H.
    Kwon, Min J.
    Chung, Hye S.
    Yoon, Chang S.
    Jun, Hye J.
    Ko, Jung H.
    Kim, Tae K.
    Lee, Soon H.
    Oh, Min K.
    Rhee, Byoung D.
    Park, Jeong H.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2011, 92 (03) : 322 - 328
  • [7] Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study
    Toru Kato
    Teruo Inoue
    Koichi Node
    Cardiovascular Diabetology, 9
  • [8] Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study
    Kato, Toru
    Inoue, Teruo
    Node, Koichi
    CARDIOVASCULAR DIABETOLOGY, 2010, 9
  • [9] A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes
    Barnett, AH
    Anderson, DM
    Shelley, S
    Morgan, R
    Owens, DR
    DIABETES OBESITY & METABOLISM, 2004, 6 (02): : 104 - 113
  • [10] Acarbose diminishes postprandial suppression of bone resorption in patients with type 2 diabetes
    Dalsgaard, Niels B.
    Gasbjerg, Laerke S.
    Helsted, Mads M.
    Hansen, Laura S.
    Hansen, Nina L.
    Skov-Jeppesen, Kirsa
    Hartmann, Bolette
    Holst, Jens J.
    Vilsboll, Tina
    Knop, Filip K.
    BONE, 2023, 170
12345